Q32 Bio News

Aktie
WKN:  A4ZZ0Z ISIN:  US7469641051 US-Symbol:  QTTB Branche:  Biotechnologie Land:  USA
6,05 €
-0,175 €
-2,81%
27.03.26
Depot/Watchlist
Marktkapitalisierung *
33,16 Mio. €
Streubesitz
29,10%
KGV
-0,88
Index-Zuordnung
-

Q32 Bio News

10.03.26 - PR Newswire
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
18.02.26 - PR Newswire
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference PR Newswire
17.02.26 - PR Newswire
Q32 Bio Announces $10.5 Million Registered Direct Offering
Q32 Bio Announces $10.5 Million Registered Direct Offering PR Newswire
01.12.25 - PR Newswire
Q32 Bio Sells Complement Inhibitor ADX-097
Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire
13.11.25 - PR Newswire
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
21.10.25 - PR Newswire
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata PR Newswire
28.08.25 - PR Newswire
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
06.08.25 - PR Newswire
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
25.06.25 - PR Newswire
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer PR Newswire
08.05.25 - PR Newswire
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
30.04.25 - PR Newswire
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata PR Newswire
16.04.25 - PR Newswire
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Q32 Bio Doses First Patients in Both Part A Open-​Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata PR Newswire

Newssuche

Videos

newspaper
23.03.26 +6,96%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »